The immunosuppressive drug sirolimus considerably improves the kidney health of patients with autosomal dominant polycystic kidney disease (ADPKD), according to a new study. The results suggest that this agent may be a promising treatment option for patients with ADPKD -- the most common genetic kidney disease and a major cause of kidney failure.